1) |
Posadas SJ and Pichler WJ.:Delayed drug
hypersensitivity reactions - new concepts. Clin. Exp.
Allergy, 37: 989-399, 2007. |
2) |
Dean JH, et al.:ICCVAM evaluation of the
murine local lymph node assay. Conclusion and
recommendations of an independent scientific peer
review panel. Regul. Toxicol. Pharmacol., 34: 258-273,
2001. |
3) |
OECD Guideline 429: OECD Guideline for the Testing
of Chemicals. Skin Sensitization: Local Lymph Node
Assay. http://www.oecd-ilibrary.org/environment/test-no-429-skin-sensitisation_9789264071100-en |
4) |
OECD Guideline 442A: OECD Guideline for the
testing of chemicals. Skin Sensitization: Local
Lymph Node Assay:DA .http://www.oecd-ilibrar y.org/environment/test-no-442a-skinsensitization_9789264090972-en |
5) |
OECD Guideline 442B: OECD Guideline for the
testing of chemicals. Skin ensitization: Local
Lymph Node Assay: BrdU-ELISA. http://www.oecd-ilibrary.org/environment/test-no-442b-skinsensitization_9789264090996-en |
6) |
医薬品非臨床ガイドライン解説2010. 2-7 皮膚感作性試験, 薬事日報社, 2010 |
7) |
Aeby P, et al.: Identifying and characterizing
chemical skin sensitizers without animal testing:
Colipa's research and method development program.
Toxicol. In Vitro. 24: 1465-1473, 2010. |
8) |
Sakaguchi H, et al.: Predicting skin sensitization
potential and inter-laboratory reproducibility of a
human Cell Line Activation Test( h-CLAT) in the
European Cosmetics Association( COLIPA) ring
trials. Toxicol. In Vitro. 24: 1810-1820, 2010. |
9) |
Martin SF, et al.: T-cell recognition of chemicals,
protein allergens and drugs:towards the
development of in vitro assays. Cell. Mol. Life Sci., 67:
4171-4184, 2010. |
10) |
澤田純一、手島玲子:医薬品等の非臨床アレルゲン性試験とその問題. アレルギーの臨床, 20:104-110,2000. |
11) |
Weaver JL , et al.:Detection of systemic
hypersensitivity to drugs using standard guinea pig
assays. Toxicology, 193: 203-217, 2003. |
12) |
食品安全委員会:添加物に関する食品健康影響評価指針(平成22年5月27日決定) |
13) |
Codex Alimentarius Guideline(GL45-2003): Guideline
for the conduct of food safety assessment of foods
derived from recombinant-DNA plants. Annex 1.
Assessment of possible allergenicity. |
14) |
食品安全委員会:遺伝子組換え食品(種子植物)の安全性評価基準(平成16年1月29日決定);遺伝子組換え食品(微生物)の安全性評価基準((平成20年6月26日決定)」) |
15) |
新見伸吾、他: 治療用タンパク質の免疫原性 その1.医薬品研究, 40:703-715, 2009. |
16) |
Ghaderi D, et al.: Implications of the presence
of N-glycolylneuraminic acid in recombinant
therapeutic glycoproteins. Nat. Biotechnol., 28: 863-867, 2010. |
17) |
Chung CH, et al.: Cetuximab-induced anaphylaxis
and IgE specific for galactose-α-1,3-galactose. N.
Engl. J. Med., 358: 1109-1117, 2008. |
18) |
新見伸吾、他:治療用タンパク質の免疫原性 その2.医薬品医療機器レギュラトリーサイエンス, 41:390,2010. |